Institutional members access full text with Ovid®

Share this article on:

Non-alcoholic steatohepatitis

Jansen, Peter LM

European Journal of Gastroenterology & Hepatology: November 2004 - Volume 16 - Issue 11 - p 1079-1085
Review in Depth

Review in Depth 1079 Introduction Peter L.M. Jansen

1087 The epidemiology of fatty liver Stefano Bellantani, Giorgio Bedogni, Lucia Miglioli and Claudio Tiribelli

1095 Mitochondrial injury in steatohepatitis Dominique Pessayre, Bernard Fromenty and Abdellah Mansouri

1107 Role of liver biopsy in the assessment of non-alcoholic fatty liver disease Stefan G. Hübscher

1117 Evaluation and management of non-alcoholic steatohepatitis B. Marie Reid and Arun J. Sanyal

Introduction Peter L.M. Jansen Non-alcoholic steatohepatitis (NASH) is an underdiagnosed liver disease characterized by steatosis, necroinflammation and fibrosis. This disease may eventually develop into cirrhosis and hepatocellular carcinoma. NASH is highly prevalent among obese individuals and among patients with diabetes mellitus type 2. Non-alcoholic fatty liver (NAFL), a precursor of NASH, is the main cause of elevated serum liver enzymes among the general population. In NASH the liver is programmed to lipogenesis rather than to glycogenesis and herein insulin-resistance plays a major role. Gradual weight loss, physical exercise and drugs that improve insulin sensitivity are potential therapies.

Department of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, the Netherlands.

Correspondence to Professor Dr Peter L.M. Jansen, Department of Gastroenterology and Hepatology, Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands. E-mail: pljansen@amc.uva.nl

© 2004 Lippincott Williams & Wilkins, Inc.